Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
This NA trial investigates HIV Infections and is currently completed. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections leads this study, which shows 9 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2024 — Jul 2024 [monthly]
Completed NA
-
Dec 2021 — Jun 2024 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Oct 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Aurora, United States
- • Boston, United States
- • Chapel Hill, United States
- • Columbus, United States
- • New York, United States
- • San Juan, Puerto Rico
- • St Louis, United States